MannKind traded at $3.93 this Friday August 19th, decreasing $0.07 or 1.75 percent since the previous trading session. Looking back, over the last four weeks, MannKind lost 6.22 percent. Over the last 12 months, its price fell by 6.87 percent. Looking ahead, we forecast MannKind to be priced at 4.03 by the end of this quarter and at 3.70 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
3.93
Daily Change
-1.75%
Yearly
-6.87%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Adma Biologics 2.58 0.07 2.59% 111.07%
BioCryst Pharmaceuticals 14.11 -0.22 -1.54% -0.70%
ChemoCentryx 51.05 0.05 0.10% 260.01%
Dynavax Technologies 12.19 -0.28 -2.25% 1.25%
Halozyme Therapeutics 42.41 -0.70 -1.63% 7.22%
Immunogen 5.75 -0.13 -2.13% 8.40%
Insmed 25.32 -0.38 -1.48% 7.42%
Jazz Pharmaceuticals 156.02 -0.53 -0.34% 16.87%
Karyopharm Therapeutics 5.37 -0.14 -2.45% 15.87%
Eli Lilly 324.74 8.02 2.53% 19.87%
MacroGenics 4.17 -0.23 -5.23% -81.03%
MannKind 3.93 -0.07 -1.75% -6.87%
Merck & Co 92.75 1.35 1.48% 17.88%
Minerva Neurosciences 3.13 -0.27 -7.94% 71.03%
Novavax 36.28 -0.90 -2.42% -84.29%
Novo Nordisk A Fs 105.11 2.35 2.29% -1.42%
Pfizer 49.39 0.81 1.67% 1.38%
Peregrine Pharmaceuticals 18.45 -0.59 -3.10% -25.60%
Sanofi 81.66 -0.06 -0.07% -10.00%
Xencor 29.78 -0.15 -0.50% -6.18%

Indexes Price Day Year
USND 12687 -278.22 -2.15% -13.78%
US2000 1957 -44.18 -2.21% -9.74%

MannKind
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.